Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KATHERINE B REED

Allopathic & Osteopathic Physicians Dermatology

NPI
1396919569
CMS profile
335358
Location
SPOKANE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$547.33

32 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $547.33 32

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KATHERINE B REED

NPI 1396919569 · CMS profile ID 335358

Allopathic & Osteopathic Physicians / Dermatology

SPOKANE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1396919569?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KATHERINE B REED, NPI 1396919569, CMS profile ID 335358. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396919569?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). KATHERINE B REED, NPI 1396919569, CMS profile ID 335358. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396919569?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
KATHERINE B REED, NPI 1396919569, CMS profile ID 335358, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1396919569?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

32 matching records · $547.33 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 32 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–32 of 32.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $15.0711/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694219337 CMS
Lilly USA, LLC $17.4011/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657930113 CMS
Novartis Pharmaceuticals Corporation $13.0710/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659860567 CMS
Biofrontera Inc. $7.7710/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 690544023 CMS
AbbVie, Inc. $18.9710/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699319 CMS
Celgene Corporation $23.9408/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672886457 CMS
Amgen Inc. $12.1208/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662591459 CMS
Novartis Pharmaceuticals Corporation $17.5708/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659860565 CMS
Lilly USA, LLC $15.8708/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657943901 CMS
AbbVie, Inc. $21.3407/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699313 CMS
Celgene Corporation $24.3607/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672886273 CMS
GENZYME CORPORATION $17.8707/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694098869 CMS
Lilly USA, LLC $18.1207/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657950651 CMS
PFIZER INC. $16.4606/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672253685 CMS
AbbVie, Inc. $17.9206/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699331 CMS
Integra LifeSciences Corporation $25.3306/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697158539 CMS
AbbVie, Inc. $15.5206/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699327 CMS
AbbVie, Inc. $17.0105/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699311 CMS
Novartis Pharmaceuticals Corporation $12.2505/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659860563 CMS
PruGen, Inc. Pharmaceuticals $13.5605/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 707764987 CMS
PFIZER INC. $18.4505/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672021947 CMS
Lilly USA, LLC $14.2405/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657930111 CMS
AbbVie, Inc. $17.1304/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699353 CMS
Amgen Inc. $13.2104/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662591457 CMS
Helsinn Therapeutics (U.S.), Inc. $15.7804/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655947391 CMS
AbbVie, Inc. $15.0403/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699325 CMS
Lilly USA, LLC $17.2003/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657950649 CMS
PFIZER INC. $20.0902/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671891609 CMS
Biofrontera Inc. $20.9702/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 667996653 CMS
PFIZER INC. $16.6502/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671853273 CMS
Lilly USA, LLC $19.9101/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657926571 CMS
AbbVie, Inc. $17.1401/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699321 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $547.33 32
PY2020 $413.54 18
PY2021 $570.86 34
PY2022 $538.17 34
PY2023 $498.08 30
PY2024 $705.53 35
PY2025 $1,169.72 67

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $734,267.33 246
PY2024 Principal investigator $853,745.12 356
PY2023 Principal investigator $644,757.85 253
PY2022 Principal investigator $361,336.03 142
PY2021 Principal investigator $277,998.71 117
PY2020 Principal investigator $149,365.00 24
PY2019 Principal investigator $53,682.69 24

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

253 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $5,243.41 12/28/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 1040838567
Principal investigator 1 Incyte Corporation $1,453.60 12/28/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Safety and Efficacy Study of Ruxolitinib Cream Combined With Narrow-Band Ultraviolet B Phototherapy in Participants With Vitiligo No dispute reported 06/30/2026 1040838591
Principal investigator 1 Horizon Therapeutics plc $51,400.04 12/20/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE PLLC
A PHASE 2A, OPEN LABEL, PROOF OF CONCEPT TRIAL OF DAXDILIMAB FOR THE TREATMENT OF MODERATE TO SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 986929121
Principal investigator 1 Incyte Corporation $62.27 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839323
Principal investigator 1 Incyte Corporation $59.13 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839341
Principal investigator 1 Incyte Corporation $135.40 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839357
Principal investigator 1 Incyte Corporation $124.54 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839373
Principal investigator 1 Incyte Corporation $118.26 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839391
Principal investigator 1 Incyte Corporation $32.88 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839407
Principal investigator 1 Incyte Corporation $49.32 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839423
Principal investigator 1 Incyte Corporation $14.58 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839441
Principal investigator 1 Incyte Corporation $57.54 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839457
Principal investigator 1 Incyte Corporation $65.76 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839473
Principal investigator 1 Incyte Corporation $19.44 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839489
Principal investigator 1 Incyte Corporation $24.30 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839507
Principal investigator 1 Incyte Corporation $82.20 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839523
Principal investigator 1 Incyte Corporation $34.02 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839539
Principal investigator 1 Incyte Corporation $36.45 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839555
Principal investigator 1 Incyte Corporation $38.88 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839574
Principal investigator 1 Incyte Corporation $43.74 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839591
Principal investigator 1 Incyte Corporation $48.60 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839607
Principal investigator 1 Incyte Corporation $124.54 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040840805
Principal investigator 1 Incyte Corporation $32.88 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040840821
Principal investigator 1 Incyte Corporation $32.88 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040840839
Principal investigator 1 Incyte Corporation $32.88 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040840855
Principal investigator 1 Incyte Corporation $49.32 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040840871
Principal investigator 1 Incyte Corporation $49.32 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040840887
Principal investigator 1 Incyte Corporation $49.32 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040840905
Principal investigator 1 Incyte Corporation $49.32 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040840925
Principal investigator 1 Incyte Corporation $49.32 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040840941
Principal investigator 1 Incyte Corporation $49.32 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040840957
Principal investigator 1 Incyte Corporation $49.32 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040840973
Principal investigator 1 Incyte Corporation $57.54 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040840991
Principal investigator 1 Incyte Corporation $57.54 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040841007
Principal investigator 1 Incyte Corporation $57.54 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040841025
Principal investigator 1 Incyte Corporation $65.76 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040841041
Principal investigator 1 Incyte Corporation $65.76 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040841059
Principal investigator 1 Incyte Corporation $65.76 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040841073
Principal investigator 1 Incyte Corporation $82.20 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040841089
Principal investigator 1 Incyte Corporation $82.20 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040841107
Principal investigator 1 Incyte Corporation $82.20 12/07/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040841123
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $41,906.54 12/04/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANEVIP
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1046267419
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,700.00 12/04/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044792039
Principal investigator 1 Incyte Corporation $1,334.00 12/04/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838877
Principal investigator 1 Incyte Corporation $1,422.00 12/04/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838893
Principal investigator 1 Incyte Corporation $1,461.00 12/04/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838905
Principal investigator 1 Incyte Corporation $1,473.00 12/04/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838921
Principal investigator 1 Incyte Corporation $1,334.00 12/04/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040840701
Principal investigator 1 Incyte Corporation $1,334.00 12/04/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040840721
Principal investigator 1 Incyte Corporation $1,461.00 12/04/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040840737
Principal investigator 1 Incyte Corporation $1,473.00 12/04/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040840757
Principal investigator 1 Incyte Corporation $54.76 11/27/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838971
Principal investigator 1 Incyte Corporation $64.72 11/27/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838987
Principal investigator 1 Incyte Corporation $98.72 11/27/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838999
Principal investigator 1 Incyte Corporation $45.80 11/27/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839013
Principal investigator 1 Incyte Corporation $68.70 11/27/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839031
Principal investigator 1 Incyte Corporation $148.08 11/27/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839047
Principal investigator 1 Incyte Corporation $97.08 11/27/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839062
Principal investigator 1 Incyte Corporation $1.86 11/27/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839079
Principal investigator 1 Incyte Corporation $172.76 11/27/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839093
Principal investigator 1 Incyte Corporation $2.48 11/27/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839107
Principal investigator 1 Incyte Corporation $129.44 11/27/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839123
Principal investigator 1 Incyte Corporation $197.44 11/27/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839137
Principal investigator 1 Incyte Corporation $145.62 11/27/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839153
Principal investigator 1 Incyte Corporation $103.05 11/27/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839169
Principal investigator 1 Incyte Corporation $161.80 11/27/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839187
Principal investigator 1 Incyte Corporation $246.80 11/27/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839205
Principal investigator 1 Incyte Corporation $114.50 11/27/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839223
Principal investigator 1 Incyte Corporation $3.72 11/27/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839241
Principal investigator 1 Incyte Corporation $226.52 11/27/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839257
Principal investigator 1 Incyte Corporation $171.75 11/27/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839273
Principal investigator 1 Incyte Corporation $4.96 11/27/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839289
Principal investigator 1 Incyte Corporation $5.58 11/27/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839307
Principal investigator 1 Incyte Corporation $148.08 11/27/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040840771
Principal investigator 1 Incyte Corporation $4.96 11/27/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040840791
Principal investigator 1 Incyte Corporation $100.00 11/22/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838827
Principal investigator 1 Incyte Corporation $810.00 11/22/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838845
Principal investigator 1 Incyte Corporation $756.00 11/22/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838861
Principal investigator 1 Incyte Corporation $57.00 11/22/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838955
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $500.00 11/10/2023 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 1056332839
Principal investigator 1 Arcutis Biotherapeutics, Inc. $11,138.98 11/06/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044792067
Principal investigator 1 Incyte Corporation $1,334.00 11/06/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838745
Principal investigator 1 Incyte Corporation $1,473.00 11/06/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838761
Principal investigator 1 Incyte Corporation $1,422.00 11/06/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838779
Principal investigator 1 Incyte Corporation $1,461.00 11/06/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838795
Principal investigator 1 Incyte Corporation $2,128.00 11/06/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838811
Principal investigator 1 Incyte Corporation $1,473.00 11/06/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839813
Principal investigator 1 Incyte Corporation $1,473.00 11/06/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839831
Principal investigator 1 Incyte Corporation $1,422.00 11/06/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839847
Principal investigator 1 Incyte Corporation $2,128.00 11/06/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839863
Principal investigator 1 Incyte Corporation $1,422.00 11/06/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839879
Principal investigator 1 Incyte Corporation $1,012.26 11/01/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1040838555
Principal investigator 1 Incyte Corporation $3,357.78 11/01/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Mechanism of Action of Ruxolitinib Cream for Vitiligo No dispute reported 06/30/2026 1040838579
Principal investigator 1 Incyte Corporation $1,000.00 11/01/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838605
Principal investigator 1 Incyte Corporation $300.00 10/18/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838699
Principal investigator 1 Incyte Corporation $672.00 10/18/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838713
Principal investigator 1 Incyte Corporation $1,000.00 10/18/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838729
Principal investigator 1 Incyte Corporation $171.00 10/18/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838939
Principal investigator 1 Incyte Corporation $2,266.00 10/11/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838617
Principal investigator 1 Incyte Corporation $1,334.00 10/11/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838629
Principal investigator 1 Incyte Corporation $1,422.00 10/11/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838641
Principal investigator 1 Incyte Corporation $1,461.00 10/11/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838653
Principal investigator 1 Incyte Corporation $2,128.00 10/11/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838671
Principal investigator 1 Incyte Corporation $1,875.00 10/11/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838687
Principal investigator 1 Incyte Corporation $1,334.00 10/11/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839625
Principal investigator 1 Incyte Corporation $1,422.00 10/11/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839641
Principal investigator 1 Incyte Corporation $1,461.00 10/11/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839659
Principal investigator 1 Incyte Corporation $1,461.00 10/11/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839675
Principal investigator 1 Incyte Corporation $1,334.00 10/11/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839691
Principal investigator 1 Incyte Corporation $2,128.00 10/11/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839707
Principal investigator 1 Incyte Corporation $1,422.00 10/11/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839723
Principal investigator 1 Incyte Corporation $1,334.00 10/11/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839739
Principal investigator 1 Incyte Corporation $1,422.00 10/11/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839765
Principal investigator 1 Incyte Corporation $1,334.00 10/11/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839777
Principal investigator 1 Incyte Corporation $1,461.00 10/11/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040839793
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $2,150.00 10/04/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1046142569
Principal investigator 1 Arcutis Biotherapeutics, Inc. $316.89 10/04/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044792103
Principal investigator 1 Incyte Corporation $1,859.08 10/04/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1040838531
Principal investigator 1 Incyte Corporation $2,710.50 10/04/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1040838543
Principal investigator 1 Incyte Corporation $1,030.00 09/28/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Mechanism of Action of Ruxolitinib Cream for Vitiligo No dispute reported 06/30/2026 1040838383
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $50.00 09/18/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1045932441
Principal investigator 1 Incyte Corporation $19,968.00 09/06/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838453
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $7,900.00 09/05/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1046169755
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,098.20 09/05/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044791973
Principal investigator 1 Incyte Corporation $3,204.99 08/30/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1040838321
Principal investigator 1 Incyte Corporation $2,125.80 08/30/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Safety and Efficacy Study of Ruxolitinib Cream Combined With Narrow-Band Ultraviolet B Phototherapy in Participants With Vitiligo No dispute reported 06/30/2026 1040838359
Principal investigator 1 Arcutis Biotherapeutics, Inc. $600.00 08/28/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044791939
Principal investigator 1 Incyte Corporation $150.00 08/24/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 1040838335
Principal investigator 1 Incyte Corporation $3,025.00 08/23/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838407
Principal investigator 1 Incyte Corporation $1,996.00 08/23/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838419
Principal investigator 1 Incyte Corporation $2,484.00 08/23/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838431
Principal investigator 1 Incyte Corporation $600.00 08/23/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838441
Principal investigator 1 Incyte Corporation $1,485.00 08/17/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1040838309
Principal investigator 1 Incyte Corporation $2,694.90 08/10/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Safety and Efficacy Study of Ruxolitinib Cream Combined With Narrow-Band Ultraviolet B Phototherapy in Participants With Vitiligo No dispute reported 06/30/2026 1040838347
Principal investigator 1 Incyte Corporation $41,289.00 08/09/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838395
Principal investigator 1 Incyte Corporation $1,952.22 08/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1040838297
Principal investigator 1 Incyte Corporation $2,710.50 08/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1040838371
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $3,449.85 07/26/2023 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 1056332579
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $4,440.00 07/24/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1045996799
Principal investigator 1 Incyte Corporation $525.00 07/19/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1040838087
Principal investigator 1 Incyte Corporation $800.00 07/19/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838465
Principal investigator 1 Incyte Corporation $1,070.00 07/19/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838481
Principal investigator 1 Incyte Corporation $456.00 07/19/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838495
Principal investigator 1 Incyte Corporation $966.00 07/19/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838507
Principal investigator 1 Incyte Corporation $12,751.00 07/19/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040838519
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $650.00 07/17/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1045977205
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $740.00 07/17/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1046080121
Principal investigator 1 Incyte Corporation $450.00 07/13/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Safety and Efficacy Study of Ruxolitinib Cream Combined With Narrow-Band Ultraviolet B Phototherapy in Participants With Vitiligo No dispute reported 06/30/2026 1040838247
Principal investigator 1 Incyte Corporation $3,025.76 07/06/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1040838075
Principal investigator 1 Incyte Corporation $8,131.50 07/06/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1040838285
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $3,187.50 07/04/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1046171083
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,247.38 07/04/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044791905
Principal investigator 1 Arcutis Biotherapeutics, Inc. $5,013.00 07/04/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044792007
Principal investigator 1 Incyte Corporation $636.00 06/22/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 1040838161
Principal investigator 1 Almirall LLC $1,206.55 06/19/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE-VIP
M14867-32 No dispute reported 06/30/2026 1061983204
Principal investigator 1 Arcutis Biotherapeutics, Inc. $385.00 06/19/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044791701
Principal investigator 1 Incyte Corporation $500.00 06/16/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837473
Principal investigator 1 ABBVIE INC. $498.00 06/15/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 998387289
Principal investigator 1 Incyte Corporation $5,391.52 06/08/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 1040838111
Principal investigator 1 Incyte Corporation $1,250.00 06/08/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1040838273
Principal investigator 1 Incyte Corporation $199.12 06/05/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837463
Principal investigator 1 Incyte Corporation $20,521.00 06/05/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837561
Principal investigator 1 Incyte Corporation $2,024.52 06/03/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1040838063
Principal investigator 1 Incyte Corporation $135.00 06/03/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Mechanism of Action of Ruxolitinib Cream for Vitiligo No dispute reported 06/30/2026 1040838185
Principal investigator 1 Incyte Corporation $4,145.85 06/03/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Safety and Efficacy Study of Ruxolitinib Cream Combined With Narrow-Band Ultraviolet B Phototherapy in Participants With Vitiligo No dispute reported 06/30/2026 1040838235
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $4,812.06 05/29/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1046173245
Principal investigator 1 Arcutis Biotherapeutics, Inc. $3,329.88 05/29/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044791673
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,649.85 05/29/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044791742
Principal investigator 1 Incyte Corporation $500.00 05/25/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837549
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $1,675.00 05/16/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1046172591
Principal investigator 1 Incyte Corporation $22,985.00 05/08/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837537
Principal investigator 1 Incyte Corporation $3,991.45 05/03/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1040838051
Principal investigator 1 Incyte Corporation $11,973.00 05/03/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Safety and Efficacy Study of Ruxolitinib Cream Combined With Narrow-Band Ultraviolet B Phototherapy in Participants With Vitiligo No dispute reported 06/30/2026 1040838223
Principal investigator 1 Incyte Corporation $8,491.00 05/03/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1040838261
Principal investigator 1 Incyte Corporation $42.59 05/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837611
Principal investigator 1 Incyte Corporation $75.61 05/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837623
Principal investigator 1 Incyte Corporation $23.95 05/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837635
Principal investigator 1 Incyte Corporation $41.58 05/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837647
Principal investigator 1 Incyte Corporation $22.29 05/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837659
Principal investigator 1 Incyte Corporation $22.90 05/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837671
Principal investigator 1 Incyte Corporation $32.36 05/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837683
Principal investigator 1 Incyte Corporation $61.70 05/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837695
Principal investigator 1 Incyte Corporation $48.54 05/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837711
Principal investigator 1 Incyte Corporation $3.20 05/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837723
Principal investigator 1 Incyte Corporation $4.04 05/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837735
Principal investigator 1 Incyte Corporation $64.72 05/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837747
Principal investigator 1 Incyte Corporation $6.06 05/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837759
Principal investigator 1 Incyte Corporation $7.60 05/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837771
Principal investigator 1 Incyte Corporation $6.80 05/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837783
Principal investigator 1 Incyte Corporation $6.00 05/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837795
Principal investigator 1 Incyte Corporation $10.10 05/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837807
Principal investigator 1 Incyte Corporation $149.90 05/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837819
Principal investigator 1 Incyte Corporation $179.88 05/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837831
Principal investigator 1 Incyte Corporation $22.90 05/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837843
Principal investigator 1 Incyte Corporation $22.90 05/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837855
Principal investigator 1 Incyte Corporation $22.90 05/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837867
Principal investigator 1 Incyte Corporation $61.70 05/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837879
Principal investigator 1 Incyte Corporation $22.90 05/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837893
Principal investigator 1 Incyte Corporation $32.36 05/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837905
Principal investigator 1 Incyte Corporation $22.90 05/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837917
Principal investigator 1 Incyte Corporation $22.90 05/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837929
Principal investigator 1 Incyte Corporation $32.36 05/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837943
Principal investigator 1 Incyte Corporation $32.36 05/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837955
Principal investigator 1 Incyte Corporation $32.36 05/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837963
Principal investigator 1 Incyte Corporation $48.54 05/02/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837975
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $1,673.44 05/01/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1046173227
Principal investigator 1 Almirall LLC $2,200.00 05/01/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE-VIP
M14867-32 No dispute reported 06/30/2026 1061983202
Principal investigator 1 Arcutis Biotherapeutics, Inc. $2,843.25 05/01/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044791611
Principal investigator 1 Arcutis Biotherapeutics, Inc. $2,307.84 05/01/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044791841
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $2,592.76 04/26/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1046142551
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $3,700.00 04/26/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1046170435
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $370.00 04/26/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1046173265
Principal investigator 1 Arcutis Biotherapeutics, Inc. $75.00 04/26/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044791777
Principal investigator 1 ABBVIE INC. $6,894.14 04/25/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis No dispute reported 06/30/2026 998379427
Principal investigator 1 ABBVIE INC. $3,000.00 04/25/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis No dispute reported 06/30/2026 998379429
Principal investigator 1 Incyte Corporation $6,318.00 04/12/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837509
Principal investigator 1 Incyte Corporation $5,602.00 04/05/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837523
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $3,019.62 04/03/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1045990309
Principal investigator 1 Arcutis Biotherapeutics, Inc. $829.18 04/03/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044791639
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,700.00 04/03/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044791811
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,700.00 04/03/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044791873
Principal investigator 1 Incyte Corporation $2,000.00 04/03/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837485
Principal investigator 1 Incyte Corporation $7,500.00 04/03/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837497
Principal investigator 1 Incyte Corporation $1,000.00 04/01/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1040838039
Principal investigator 1 Incyte Corporation $10,910.98 03/29/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1040838025
Principal investigator 1 Incyte Corporation $24,733.37 03/29/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Safety and Efficacy Study of Ruxolitinib Cream Combined With Narrow-Band Ultraviolet B Phototherapy in Participants With Vitiligo No dispute reported 06/30/2026 1040838209
Principal investigator 1 Incyte Corporation $7,500.00 03/24/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837175
Principal investigator 1 Incyte Corporation $2,000.00 03/24/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837185
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $30.14 03/22/2023 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 1056332319
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $1,832.45 03/22/2023 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 1056332337
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $14.00 03/21/2023 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 1056332373
Principal investigator 1 Incyte Corporation $106.00 03/09/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 1040838149
Principal investigator 1 Incyte Corporation $4,141.00 03/06/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040837041
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $1,742.01 03/06/2023 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 1056332245
Principal investigator 1 Incyte Corporation $1,030.00 03/03/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 1040838099
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $5,640.00 03/03/2023 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 1056332175
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $60,079.50 03/03/2023 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 1056332193
Principal investigator 1 Incyte Corporation $5,035.59 03/01/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1040838011
Principal investigator 1 Incyte Corporation $4,075.11 03/01/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 1040838135
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,478.66 02/27/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044791513
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,100.00 02/27/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044791545
Principal investigator 1 Almirall LLC $2,284.34 02/20/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE-VIP
M14867-32 No dispute reported 06/30/2026 1061983200
Principal investigator 1 ABBVIE INC. $1,892.80 02/09/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis No dispute reported 06/30/2026 998369405
Principal investigator 1 Incyte Corporation $1,791.68 02/01/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1040838001
Principal investigator 1 Incyte Corporation $212.00 02/01/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 1040838123
Principal investigator 1 Incyte Corporation $1,113.84 02/01/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Mechanism of Action of Ruxolitinib Cream for Vitiligo No dispute reported 06/30/2026 1040838173
Principal investigator 1 Incyte Corporation $13,292.62 02/01/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Safety and Efficacy Study of Ruxolitinib Cream Combined With Narrow-Band Ultraviolet B Phototherapy in Participants With Vitiligo No dispute reported 06/30/2026 1040838199
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $4,595.32 01/30/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1046017401
Principal investigator 1 Arcutis Biotherapeutics, Inc. $3,025.74 01/30/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044791475
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $1,000.00 01/26/2023 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 1056332109
Principal investigator 1 Almirall LLC $1,679.50 01/09/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE-VIP
M14867-32 No dispute reported 06/30/2026 1061983198
Principal investigator 1 Arcutis Biotherapeutics, Inc. $149.18 01/09/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044791577
Principal investigator 1 Incyte Corporation $300.00 01/09/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1040837987